Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
作者： Edwin Choy , Yael Flamand , Sriram Balasubramanian , James E. Butrynski , David C. Harmon
DOI: 10.1002/CNCR.29175
关键词: Doxorubicin 、 Histone deacetylase 、 Cancer research 、 Apoptosis 、 Medicine 、 Immunology 、 Granulocyte colony-stimulating factor 、 Histone deacetylase inhibitor 、 Toxicity 、 Abexinostat 、 Sarcoma
摘要: Introduction Several inhibitors of histone deacetylase have been shown to enhance chemotherapy induced apoptosis and reduce sarcoma tumor volume in preclinical models. We sought determine the MTD, PK/PD, safety toxicity inhibitor (HDACi) abexinostat (PCI-24781) when administered with doxorubicin patients metastatic sarcomas.
sci-hub.se 参考文章(22)
Shunsaku Yamamoto, Kazuhiro Tanaka, Riku Sakimura, Takamitsu Okada, Tomoyuki Nakamura, Yan Li, Minoru Takasaki, Yusaku Nakabeppu, Yukihide Iwamoto, None, Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines. Anticancer Research. ,vol. 28, pp. 1585- 1591 ,(2008)
Vivien Bramwell, Dale Anderson, Manya Charette, , Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database of Systematic Reviews. ,vol. 2003, ,(2003) , 10.1002/14651858.CD003293
Cao Yang, Edwin Choy, Francis J. Hornicek, Kirkham B. Wood, Joseph H. Schwab, Xianzhe Liu, Henry Mankin, Zhenfeng Duan, Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells. Cancer Chemotherapy and Pharmacology. ,vol. 67, pp. 439- 446 ,(2011) , 10.1007/S00280-010-1344-7
Sabrina Ehnert, Jian Zhao, Stefan Pscherer, Thomas Freude, Steven Dooley, Andreas Kolk, Ulrich Stöckle, Andreas Klaus Nussler, Robert Hube, Transforming growth factor β1 inhibits bone morphogenic protein (BMP)-2 and BMP-7 signaling via upregulation of Ski-related novel protein N (SnoN): possible mechanism for the failure of BMP therapy? BMC Medicine. ,vol. 10, pp. 101- 101 ,(2012) , 10.1186/1741-7015-10-101
Marina Pacheco, Torsten O Nielsen, Histone deacetylase 1 and 2 in mesenchymal tumors. Modern Pathology. ,vol. 25, pp. 222- 230 ,(2012) , 10.1038/MODPATHOL.2011.157
Riku Sakimura, Kazuhiro Tanaka, Syunsaku Yamamoto, Tomoya Matsunobu, Xu Li, Masuo Hanada, Takamitsu Okada, Tomoyuki Nakamura, Yang Li, Yukihide Iwamoto, None, The effects of histone deacetylase inhibitors on the induction of differentiation in chondrosarcoma cells Clinical Cancer Research. ,vol. 13, pp. 275- 282 ,(2007) , 10.1158/1078-0432.CCR-06-1696
Erik R. Sampson, Vinit Amin, Edward M. Schwarz, Regis J. O'Keefe, Randy N. Rosier, The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy. Journal of Orthopaedic Research. ,vol. 29, pp. 623- 632 ,(2011) , 10.1002/JOR.21274
Dina C. Lev, Gonzalo Lopez, Juehui Liu, Wenhong Ren, Wei Wei, Suizhao Wang, Guy Lahat, Quan-Sheng Zhu, William G. Bornmann, David J. McConkey, Raphael E. Pollock, Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clinical Cancer Research. ,vol. 15, pp. 3472- 3483 ,(2009) , 10.1158/1078-0432.CCR-08-2714
S. Adimoolam, M. Sirisawad, J. Chen, P. Thiemann, J. M. Ford, J. J. Buggy, HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 104, pp. 19482- 19487 ,(2007) , 10.1073/PNAS.0707828104
Luke A. Wittenburg, Liam Bisson, Barbara J. Rose, Christopher Korch, Douglas H. Thamm, The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin Cancer Chemotherapy and Pharmacology. ,vol. 67, pp. 83- 92 ,(2011) , 10.1007/S00280-010-1287-Z